Page 7 - நிறுவனம் ஆஃப் நுண்ணுயிரியல் சீன கலைக்கழகம் அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article SUZHOU, China, March 7, 2021 /PRNewswire/ Recently,  CMAB Biopharma (Suzhou) Inc s ( CMAB ) partner Shanghai Junshi Biosciences Co., Ltd. ( Junshi Biosciences ) (HK: 1877; SH: 688180), announced that a clinical trial application for its PD-1/TGF-β bifunctional fusion protein JS201 injection (JS201) has been accepted by National Medical Products Administration (NMPA). JS201 is a bifunctional fusion protein developed by Junshi using its proprietary technology that can simultaneously target PD-1 and TGF-β (transforming growth factor-β). JS201 is the first product targeting PD-1/TGF-β approved for a clinical trial application in China. JS201 can effectively block the immunosuppressive pathways of PD-1 and TGF-β which improves the immunomodulatory effect in the tumor microenvironment, thereby promoting the killing effect of the patient s immune system on tumor cells and reducing the occurrence of immune escape and drug resistance.

United statesSan franciscoJunshi biosciencesYongzhong wangEli lillyInstitute of microbiology chinese academy scienceBiopharma suzhou incNational medical products administrationShanghai junshi biosciences co ltdMicrobiology chinese academyQualified personCmab biopharma suzhou incஒன்றுபட்டது மாநிலங்களில்சான் பிரான்சிஸ்கோஎலி லில்லிநிறுவனம் ஆஃப் நுண்ணுயிரியல் சீன கலைக்கழகம் அறிவியல்